5:32 PM
 | 
Dec 19, 2012
 |  BC Extra  |  Company News

GlycoVaxyn, GSK in deal for bacterial vaccines

GlycoVaxyn AG (Schlieren, Switzerland) partnered with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to use GlycoVaxyn's bio-conjugation technology to develop new bacterial vaccines against an undisclosed set of...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >